Phepelo ea Feme 4-Bromo-2-Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7

Ho phethahatsa khotsofalo e lebelletsoeng ho feta tekano ea bareki, joale re na le basebetsi ba rona ba matla ho fana ka thuso ea rona e kholo ka ho fetesisa e kenyelletsang ho khothaletsa, thekiso e felletseng, moralo, popo, taolo ea boleng bo holimo, ho paka, ho boloka thepa le thepa bakeng sa Feme ea Feme ea 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Re tšepahala ebile re bulehile.Re labalabela ketelo ea hau le ho theha likamano tse tšepahalang le tsa nako e telele.
Ho phethahatsa khotsofalo e lebelletsoeng ho feta tekano ea bareki, joale re na le basebetsi ba rona ba matla ho fana ka thuso ea rona e kholo ka ho fetesisa e kenyelletsang ho khothaletsa, thekiso e felletseng, thero, popo, taolo ea boleng bo holimo, ho paka, ho boloka thepa le thepa ea thepa.China CAS 112704-79-7 le 112704-79-7, Thepa ea rona e hapile botumo bo botle ho e 'ngoe le e 'ngoe ea lichaba tse amanang.Hobane ho theha feme ea rona.re tsitlalletse ho nchafatsa mokhoa oa rona oa tlhahiso hammoho le mokhoa oa morao-rao oa taolo oa mehleng, ho hohelang batho ba bangata ba nang le talenta indastering ena.Re nka tharollo ea boleng bo botle e le semelo sa rona sa bohlokoahali.

1-Bromo-2-methoxy-3-nitro-benzene e sebelisoa joalo ka bohareng ba Eltrombopag .
Eltrombopag, e ntlafalitsoeng ke GlaxoSmithKline (GSK) naheng ea UK, 'me hamorao e ile ea ntlafatsoa ka kopanelo le Novartis naheng ea Switzerland, ke molek'hule oa pele o amohetsoeng oa molek'hule o se nang peptide TPO receptor agonist lefatšeng.Eltrombopag e amohetsoe ke US FDA ka 2008 bakeng sa kalafo ea idiopathic thrombocytopenic purpura (ITP), le ka 2014 bakeng sa kalafo ea anemia e matla ea aplastic (AA).Hape ke moriana oa pele o amohetsoeng ke US FDA bakeng sa kalafo ea AA lilemong tse 30 tsa morao tjena.
Ka December 2012, US FDA e ile ea amohela Eltrombopag bakeng sa phekolo ea thrombocytopenia ho bakuli ba nang le lefu la sebete le sa foleng la C (CHC), e le hore bakuli ba hepatitis C ba nang le bokooa bo bobe ka lebaka la palo e tlaase ea platelet ba ka qala le ho boloka phekolo e tloaelehileng ea interferon bakeng sa mafu a sebete.Ka February 3, 2014, GlaxoSmithKline e phatlalalitse hore FDA e fane ka katleho ea meriana ea phekolo ea Eltrombopag bakeng sa phekolo ea hemopenia ho bakuli ba nang le lik'hemik'hale tse matla tsa aplastic anemia (SAA) tse sa kang tsa arabela ka botlalo ho immunotherapy.Ka August 24, 2015, US FDA e amohetse Eltrombopag bakeng sa phekolo ea thrombocytopenia ho batho ba baholo le bana ba lilemo li 1 ho ea holimo ba nang le lefu le sa foleng la immune thrombocytopenia (ITP) ba nang le karabelo e sa lekaneng ho corticosteroids, immunoglobulins kapa splenectomy.Ka January4, 2018, Eltrombopag e ile ea amoheloa hore e ngolisoe Chaena bakeng sa phekolo ea "immune immune thrombocytopenia" (ITP).

Ho phethahatsa khotsofalo e lebelletsoeng ho feta tekano ea bareki, joale re na le basebetsi ba rona ba matla ho fana ka thuso ea rona e kholo ka ho fetesisa e kenyelletsang ho khothaletsa, thekiso e felletseng, moralo, popo, taolo ea boleng bo holimo, ho paka, ho boloka thepa le thepa bakeng sa Feme ea Feme ea 4-Bromo-2 -Fluorobenzoic Acid 4-Bromo-2-Fluorobenzoic Acid CAS 112704-79-7, Re tšepahala ebile re bulehile.Re labalabela ketelo ea hau le ho theha likamano tse tšepahalang le tsa nako e telele.
Phepelo ea FemeChina CAS 112704-79-7 le 112704-79-7, Thepa ea rona e hapile botumo bo botle ho e 'ngoe le e 'ngoe ea lichaba tse amanang.Hobane ho theha feme ea rona.re tsitlalletse ho nchafatsa mokhoa oa rona oa tlhahiso hammoho le mokhoa oa morao-rao oa taolo oa mehleng, ho hohelang batho ba bangata ba nang le talenta indastering ena.Re nka tharollo ea boleng bo botle e le semelo sa rona sa bohlokoahali.